Page last checked 2026-08-13

Copper-binding tripeptide complex (research compound) · safety

GHK-Cu side effects

Also called GHK copper peptide, GHK or copper peptide.

No controlled human trial has published a side-effect rate or safety profile for GHK-Cu. Here is what is actually known instead, and what that gap does and does not tell you.

GHK-Cu is a peptide three amino acids long holding a copper ion. It was pulled out of human blood plasma in 1973. It is sold for skin — wrinkles, firmness, scars — and for hair regrowth, and now increasingly as an injection.

Almost everything published is a cream on the surface of the skin. Where that work was blinded and measured objectively, the copper peptide did no better than its control. A 2026 review of injectable peptides says the dose, the frequency and the indications for injecting this one all remain unknown.

No completed controlled human trial has shown which dose works for GHK-Cu. There is no study-backed human dosing program to publish. Animal quantities are not converted into a human recommendation.

no human dose shown to work

Further down: when to get medical help · questions

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-13

At a glance

Common reactions listed

None published

Serious reactions listed

None published

Boxed warning

No label exists

Strongest source

no human dose shown to work

Nothing measured is not the same as nothing to find — the section below is about that difference.

When to seek medical care

Because no controlled human safety profile has been published for this compound, there is no evidence-based list of warning signs specific to it. That removes the early warning, not the risk. Any new, severe or lasting symptom belongs with a clinician. Tell them exactly what was taken.

EmergencySome symptoms should not wait for an appointment. Call emergency services (911 in the US) if they are severe, getting worse fast, or involve trouble breathing, chest pain, fainting or confusion.

3Read deeperTiming, evidence limits, and product context

Why there is no GHK-Cu side-effect profile here

There is no side-effect table on this page because there is no controlled human safety profile to build one from — and an empty table is more honest than a plausible one.

A published side-effect profile is not a summary of what people have noticed. It is the output of a specific process: a controlled trial enrolls a defined group and records every event, whether or not it looks related. It compares those rates against a control group, then publishes the result against a plan registered before the first dose. Where that process has not produced a profile, the output does not exist. Nothing stands in for it — not seller literature, not clinic protocols, not forum threads.

So the absence says something about the evidence, not about the compound. A profile nobody has measured is not a clean profile; it is an unmeasured one. Those two get confused constantly, and the confusion always runs in the direction that flatters the compound.

It is worth being blunt about the asymmetry. Rare and serious reactions are exactly the ones that scattered, self-reported experience is worst at catching. They are uncommon by definition, they can take time to appear, and they are easy to blame on something else.

The people who get them are also the least likely to come back and post an update. What shows up first in an unstudied compound is the mild and the immediate. That is a fact about how the reports get collected, not evidence about the compound.

The missing profile takes the rest of the scaffolding with it. With no approved label there is no list of who should avoid it, no documented interactions and no monitoring plan. There is no ceiling dose, and no channel carrying reports back to a regulator. Anyone taking an unapproved compound is outside all of those at once — and silence from a system that does not exist is not reassurance.

GHK-Cu has been trialled in people. Almost none of it went under the skin.

This is not an unstudied molecule. It has controlled human trials, decades as a cosmetic ingredient and a written assessment from a regulator. What it does not have is a safety record for the thing in the vial, which is an injection.

Where it was measured properly, it matched its control

Two controlled trials are worth knowing about, and neither supports the enthusiasm around this molecule. In leg ulcers, a copper-peptide cream did no better than an inert vehicle, and an older antibacterial cream beat both.

In skin after laser resurfacing, blinded evaluators and computer analysis found no advantage in how quickly redness settled, and none in wrinkles or skin quality later on.

The one measure that did separate the groups was the patients rating their own skin. That is a real result and it is the weakest kind in the study.

The regulator scoped its concern to the injection specifically

The entry a US regulator holds for this molecule is not written against the cream. Its own wording covers injectable routes, and names clumping, related impurities and limited human data as the concerns.

That is the same line this site draws: an ingredient with a long surface history, and an injected form nobody has assessed. The split was not invented here.

Whoever asked for the injectable form to be considered later withdrew the request, so the question closed without being answered either way.

People are injected with it constantly and nobody publishes the amount

Two published series between them cover many thousands of scalp injections containing copper tripeptide. Neither states how much of it was in the syringe.

One of them prints a concentration for the local anesthetic sharing that syringe and none for the copper peptide. That is not an oversight peculiar to one paper.

A reaction rate needs a denominator, and a denominator needs a dose. With neither published, the large numbers of people involved add nothing to what is known about safety.

A metal load is not the same risk as a peptide load

The active species here is a peptide holding copper, and the copper does not leave when the peptide is broken up.

Copper balance in the body is closely controlled, so pushing past that control is a different category of harm from a peptide that is simply cleared away.

Surface application raises the question much less sharply. Repeated injection is where it lives, and it is the route with no assessment behind it.

What the absence does and does not mean

Four readings of an empty safety record go around. Each one turns a missing measurement into reassurance.

The claim	What the evidence shows
Nothing serious has been reported.	Nothing has been systematically collected. A report needs a system that receives it, strips out duplicates and counts it. For an unapproved compound there is no such system, so silence is what you would get either way.
The studies look clean.	The published work is overwhelmingly in animals or too small and uncontrolled to produce a safety rate. Animal findings do not carry over to people at human doses over human timescales, and uncontrolled exposure supplies no comparison group or denominator.
People have used it for years.	Informal use is not monitoring. Years of unmeasured use produce familiarity and confidence. They do not produce a denominator, a comparison group, or a rate.
People seem to handle it well.	How well people handle a compound is measured against a control group. Without that comparison, the claim is only the writer’s impression.

No human safety profile has been published for this compound. If that changes, the results should be reported with the study size, comparison group and citation—not filled in with assumptions.

Common questions

Does GHK-Cu have known side effects?

No controlled human study has published a side-effect rate or safety profile. That describes the missing evidence, not the compound: unmeasured does not mean safe.

Is GHK-Cu safe?

The published human evidence cannot answer that either way. Reliable safety estimates need systematic collection, a total number treated and a comparison group; none is available here.

What should someone do about symptoms after taking an unapproved compound?

Take the symptom to a clinician, and say exactly what was taken, how much and for how long. Clinicians assess symptoms without needing an approved label to exist, and leaving out the detail removes the one piece of context that changes what they look for.

The schedule these reactions were recorded against, the comparisons, and the sourcing rules behind every grade on this page.

GHK-Cu — class, half-life and regulatory standing

No approved brand name is listed for GHK-Cu.

Work out the GHK-Cu draw in syringe units

Vial sizes 50 mg for GHK-Cu, each with its own concentration.

Vial, water and dose for any peptide, with GHK-Cu as one example

U-100, U-50 and U-40 barrels each read differently, including GHK-Cu

The proceedings behind the GHK-Cu note on this page

Newest entry first, with GHK-Cu among them.

The full index behind the GHK-Cu page

From label-backed entries to compounds with no established human dose, including GHK-Cu

Why some GHK-Cu values are missing on purpose

An absent value means no source carries one, including GHK-Cu